Chemical Biology Letters
Keywords: item categories
Intervertebral disc degeneration (IDD) is a major cause of chronic low back pain and spinal disability, characterized by extracellular matrix degradation, cellular senescence, apoptosis, and inflammation. Mitochondrial dysfunction contributes to IDD progression through excessive reactive oxygen species (ROS) production, mitochondrial membrane potential (Dym) loss, ATP depletion, altered mitochondrial dynamics, and impaired mitophagy. This review highlights the therapeutic potential of small molecules targeting mitochondrial dysfunction in IDD and explores their molecular targets and mechanisms of action. Compounds such as curcumin, resveratrol, icariin, polydatin, naringin, melatonin, epigallocatechin-3-gallate, MitoQ, α-lipoic acid, metformin, urolithin A, quercetin, and salvianolic acid B exhibit protective effects in experimental models. These agents modulate key signalling pathways, including Nrf2, PI3K/Akt, AMPK/mTOR/ULK1, SIRT1, SIRT3, Parkin-mediated mitophagy, and PPARγ, thereby reducing oxidative stress, apoptosis, and inflammation while preserving mitochondrial function and extracellular matrix homeostasis. Despite promising preclinical findings, clinical translation remains limited by poor bioavailability, inadequate disc penetration, dosing variability, and insufficient clinical evidence. Future research should prioritize targeted drug delivery, structural optimization, combination strategies, and well-designed clinical trials. Overall, mitochondrial-targeted small molecules offer a promising approach for developing disease-modifying therapies for IDD.
Discover more from RSYN FYI
Subscribe to get the latest posts sent to your email.